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Functional iron deficiency in adults with cystic fibrosis 
M. N. POND*, A. M. MORTON AND S. P. CONWAY 
Regional Adult Cystic Fibrosis Unit, Seacroft Hospital, Leeds, U.K. 
Functional iron deficiency (transferrin saturation < 16%) was found in 44 (62%) of 71 adult cystic fibrosis (CF) 
patients. Haemoglobin concentration and mean cell volume were lower in iron-deficient patients, in whom 
there was a non-significant trend for lower serum ferritin. Ten iron-deficient patients and two patients with 
transferrin saturation > = 16% (normal iron) were anaemic. There were no significant differences between 
iron-deficient and normal-iron patients in intake of calories, protein, iron and vitamin C as determined by 
4-day records of dietary intake. Dietary iron deficiency is not an important factor in functional iron deficiency 
in adult CF patients. Impairment of absorption by exogenous pancreatic enzyme supplements is unlikely to be 
significant as enzyme intake was the same in the two groups. Iron-deficient patients had lower Shwachman- 
Kulczycki scores and lower percent predicted forced expiratory volume in 1 s (FEV, % predicted) and forced 
vital capacity (FVC % predicted). There was a non-significant trend for higher values of white cell count and 
plasma viscosity in the iron-deficient group. Chronic inflammation is likely to be the primary cause of 
functional iron deficiency in adult CF patients. Fifteen patients completed 3-month courses of oral iron 
replacement with no deterioration in pulmonary function, but with no effect on haemoglobin concentration. 
Introduction 
The clinical significance of iron status in cystic 
fibrosis patients is unknown. Pulmonary disease in 
cystic fibrosis (CF) is characterized by an intense 
inflammatory reaction to colonizing bacteria, primar- 
ily Pseudomonas aeruginosa (1). Both mucoid and 
non-mucoid P. aeruginosa secrete the iron-avid 
siderophores, pyoverdin and pyochelin (2), in order 
to obtain iron from the host. Theoretically, iron 
deficiency may protect the host against Pseudomonal 
replication (3-Q but it also encourages growth of 
the mucoid over the non-mucoid phenotype of 
P. aeruginosa in vitro (6). The mucoid phenotype is 
associated with an enhanced host inflammatory 
response (7). 
Iron deficiency has been reported in 32% of a 
paediatric CF population (8). Possible causes of iron 
deficiency in CF include chronic inflammation (9), 
dietary deficiency (8,10,1 l), gastrointestinal blood 
loss (12) and impairment of oral absorption by 
exogenous pancreatic enzyme supplements (13). The 
authors have investigated the prevalence, clinical 
correlates and aetiology of iron deficiency in an adult 
CF population. 
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Methods 
Haemoglobin concentration, white cell count and 
erythrocyte indices were measured with a standard 
Coulter counter, and plasma viscosity was measured 
using a viscometer. Serum iron was measured 
colourimetrically, transferrin by turbidimetric analy- 
sis of transferrin-specific antibody complexes, and 
ferritin by radioimmunoassay. C-reactive protein 
(CRP) was measured nephelometrically. All measure- 
ments were undertaken as part of an annual compre- 
hensive evaluation of clinical condition in adult CF 
patients. Forced expiratory volume in 1 s (FEV,) and 
forced vital capacity (FVC) were measured with a 
Vitalograph Compact spirometer and expressed as 
percent predicted for age, sex and height. Patients 
were assigned Shwachman-Kulczycki scores as a 
measure of overall disease severity by one experi- 
enced observer (SPC) (14). Weight was expressed as 
percent predicted for age, height and sex. 
Patients completed a 4-day record of dietary 
intake, with 1 day during a weekend, using a stand- 
ardized booklet. This method has been validated 
(15). Patients received verbal instructions before 
starting the record, and the completed records were 
reviewed with them. Daily intake of energy, protein, 
iron and vitamin C was calculated from completed 
records on a personal computer using the Microdiet 
program (University of Salford, U.K.). Results were 
expressed in absolute units and as percentage of 
a 1996 W. B. Saunders Company Ltd 
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Table 1 Haematological values according to iron status 
Iron deficient Normal iron Mann-Whitney 
Transferrin 9 21 
saturation (%) 6-12 18-25 
Serum iron &mol 1 - ‘) 8.0 19.6 co.01 
5,8-l 1.1 15.9-22.9 
Total iron binding 93 88 0.53 
capacity @mol 1- ‘) 81-102 83-98 
Haemoglobin (g dl - ‘) 13.3 14.5 0.02 
12.5-14.5 13.0-15.4 
Mean cell volume (A) 85.4 89.3 0.02 
81.2-89.5 87.1-91.9 
Ferritin (ng ml ‘) 27 45 0.09 
1549 26-53 
Values are medians and interquartile ranges. 
Estimated Average Requirement (EAR) or Reference 
Nutrient Intake (RNI, defined as estimated average 
requirement plus two standard deviations, standard- 
ized for age and sex) (16), as appropriate. The daily 
intake of lipase, amylase and protease was calculated 
from the record of ingested supplemental pancreatic 
enzymes. 
FEV, low iron - 0 + 
FEV, normal iron - __(I1 
FVC low iron - II + 
FVC normal iron - 
I I I I I I I I I I I I 
Functional iron deficiency, i.e. decreased circulat- 
ing iron from any cause, was considered to be present 
when transferrin saturation was less than 16%, the 
level at which erythropoiesis is impaired (17). Sub- 
jects were then divided into iron-deficient and 
normal-iron groups for further analysis. Most of the 
parameters were not distributed normally and the 
Mann-Whitney U-test was used for comparisons 
between the two groups. Two-tailed PcO.05 was 
considered to be statistically significant. 
Q 9 q ?P a0 @ bo <Q eo 9Q$$@@ 
Pulmonary function (% predicted) 
Fig. I Boxplots of percent predicted pulmonary function 
according to iron status. 
Results 
(<25 ng ml ~ ’ males, < 10 ng ml - ’ females) and 
nine patients (20%) had a raised total iron-binding 
capacity (TIBC). Two (10%) of the normal-iron 
group were anaemic, none had a low MCV, one 
(4%) had a low serum ferritin and three (11%) had a 
raised TIBC. 
Data were available for 71 patients (36 male, 35 Shwachman-Kulczycki score (median 65 V.S. 77.5, 
female) with a wide range of disease severity. Mean P<O.Ol), FEV, % predicted (median 45 vs. 57%, 
(SD) age was 21.7 (5.9) years, Shwachman-Kulczycki PcO.01) and FVC % predicted (67 vs. 82%, P<O.Ol) 
score was 70 (16), FEV, % predicted was 54 (20), were significantly lower in the iron-deficient group, 
FVC % predicted was 74 (19), and percent predicted indicating greater disease severity. The pulmonary 
weight for height was 93 (11). No patients had function data are illustrated in Fig. 1. There was a 
received supplemental iron before data collection. non-significant trend for lower percent predicted 
Forty-four (62%) patients were iron deficient. weight for height (90 vs. 95%) in the iron-deficient 
Haemoglobin and mean cell volume (MCV) were group. Plasma viscosity was higher in the iron- 
significantly lower in the iron-deficient group (Table deficient group (1.79 vs. 1.73, P=O.O3), and white cell 
1). There was a trend for lower ferritin values in the count showed a non-significant trend for higher 
iron-deficient group but this did not reach statistical values in the iron-deficient group (median 8.1 vs. 6.5). 
significance. In the iron-deficient group, 10 patients C-reactive protein concentrations did not differ 
(23%) were anaemic (Hb ~12.5 g dl- ’ males, between the two groups. Ferritin concentration 
~11.4 g dl- ’ females), four (9%) had a low MCV did not correlate with any of the three markers of 
(~88 fl), 15 (34%) had a low serum ferritin inflammation. 
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Table 2 Dietary intake according to iron status 
Iron deficient Normal iron Mann-Whitney 
Energy (kcal) 3095 2770 0.16 
2599-3500 2201-3233 
Energy (% EAR) 134 127 
119-145 104-146 
Protein (g) 109 103 0.32 
93-127 69-120 
Protein (% RNI) 224 204 
1833252 154242 
Iron (mg) 14 14 0.90 
12-19 10-20 
Iron (% RNI) 133 133 
78-168 70-196 
Vitamin C (mg) 78 111 0.38 
43-122 63-132 
Vitamin C (% RNI) 195 268 
109-310 137-324 
Lipase units (*103) 250 150 0.15 
12wloo 110-310 
Amylase units (*103) 180 145 0.20 
72.5405 63.8-262.5 
Protease units (*103) 8.4 7.92 0.21 
6.25-14.85 3.78-l 18.5 
% EAR, percentage of Estimated Average Requirement (EAR); % RNI, percentage of 
Reference Nutrient Intake (RNI, defined as estimated average requirements plus 2 SD). 
Values are medians and interquartile ranges. 
Completed dietary intake booklets were obtained 
from 31 (70%) of the iron-deficient group and 21 
(78%) of the normal-iron group. None of the par- 
ameters or statistical outcomes in Table 2 were 
affected significantly after excluding data from the 
non-responders. Intake of calories, protein, iron and 
vitamin C was satisfactory and not significantly 
different in the two groups (Table 2). Intake of 
pancreatic enzyme supplements was similar in the 
two groups. 
Discussion 
Sixty-two percent of the study population was 
functionally deficient in iron (transferrin saturation 
< 16%). These patients had significantly lower FEV, 
% predicted, FVC % predicted, and Shwachman- 
Kulczycki scores. Percent predicted weight for height 
was lower and, although not statistically significant, 
the difference was probably blunted by five of the 
iron-deficient group receiving supplemental enteral 
nutrition compared with only one in the normal-iron 
group. Older patients with CF develop chronic 
inflammation in response to pulmonary colonization 
with P. aeruginosa (1). Plasma viscosity was signifi- 
cantly greater in the iron-deficient group. The worse 
performance markers and greater plasma viscosity in 
the iron-deficient group suggest that chronic inflam- 
mation is a major cause of iron deficiency. White cell 
count and C-reactive protein were not significantly 
different between the two groups, but this probably 
reflects the weaker correlation with clinical status of 
these markers compared with plasma viscosity (18). 
An inadequate erythroid response to hypoxia has 
been demonstrated in CF due to reduced erythro- 
poietin production and impaired availability of iron, 
mechanisms in keeping with a chronic inflammatory 
aetiology (10). 
Serum ferritin is elevated in chronic inflammatory 
states, but still correlates with grade of stainable 
marrow iron (19,20). Values are relatively higher 
for the same grade of iron staining than in nor- 
mal subjects. The variability of the inflammatory 
response in an adult CF population makes interpret- 
ation of ferritin values extremely difficult. Ferritin 
levels were slightly lower in the iron-deficient group 
but the difference was not statistically significant. 
Thirty-four percent of the iron-deficient group and 
23% of the total population had definitely reduced 
ferritin levels, indicating depleted iron stores. In 
paediatric CF populations, Erhardt found low serum 
ferritin values in 32% of patients (8) and Ater (11) 
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found ferritin values less than the median for age in 
85% of patients, and transferrin saturations less than 
16% in 28% of patients. There was no difference in 
performance markers between patients with low and 
normal ferritin in the present study or in Erhardt’s 
study, and ferritin did not correlate with any of 
the three inflammatory markers that the authors 
measured. This is not surprising, as patients with 
more severe disease will tend to have elevated ferritin 
levels despite functional iron deficiency. 
Given the difficulties of interpreting serum ferritin 
as a marker of iron stores, the authors investigated 
dietary intake with 4-day records. As pulmonary 
disease progresses, a greater dietary intake is required 
to compensate for the energy consumed in chronic 
pulmonary inflammation and in the increased work 
of breathing (21). Anorexia becomes a problem, and 
may be exacerbated by gastro-oesophageal reflux and 
reduced gut motility (12,22). Despite these concerns, 
recorded 4-day dietary intake showed good nutrition 
in both groups, with no significant differences. 
Fifty-eight percent of the iron-deficient group 
and 62% of the normal-iron group had iron in- 
takes above the RNI, which is two standard devi- 
ations above the estimated average requirement. 
Vitamin C can enhance oral iron absorption, but 
there was no difference in intake between the two 
groups. 
Zempsky et al. demonstrated short-term impair- 
ment of iron absorption with exogenous pancreatic 
enzymes in 13 stable young adults with CF, and 
also in nine age-matched controls (13). There were 
no differences in recorded enzyme intake between 
the two groups in the present study. Suppression of 
acid secretion enhances pancreatic enzyme activity 
by retarding enzyme degradation. Five (13%) of the 
iron-deficient group were receiving H, antagonists 
compared with none of the normal-iron group, but 
exclusion of these five patients from the analysis did 
not affect the statistical results. 
The present findings of greater disease severity in 
the iron-deficient group do not support the hypoth- 
esis that higher transferrin saturations adversely 
affect clinical status by promoting bacterial repli- 
cation. Fifteen of the iron-deficient group who com- 
pleted a 3-month course of ferrous sulphate 200 mg 
three times daily had spirometry recorded at 
2-monthly intervals for 1 yr before and after starting 
supplemental iron therapy. In this small group, the 
group mean FEV, % predicted was 53% before and 
52% after starting treatment (P=n.s.) and group 
mean FVC% predicted was 86% and 84% (P=n.s.), 
but there was no improvement in haemoglobin 
concentration. 
Although the authors found 62% of the study 
population with CF to have a functional deficiency, 
only 35% of iron-deficient patients had low serum 
ferritin values, and hence only 34% definitely had low 
iron stores. Functional iron deficiency will not be 
reliably detected by relying on ferritin estimations 
alone. Iron-deficient patients had worse performance 
markers than patients with normal serum iron, sug- 
gesting that the primary cause of the iron deficit was 
chronic inflammation. There was no evidence of a 
dietary deficiency in the study population. The 
present data do not support a significant role for 
inhibition of absorption by exogenous pancreatic 
enzymes. Occult gastrointestinal blood loss, particu- 
larly from gastro-oesophageal reflux, may account 
for the minority of patients with low serum ferritin. 
Iron-replacement therapy is probably safe in func- 
tional deficiency, but is not of proven benefit in this 
open case control study. 
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